Clinical Trial Update: VA106483 Dose Response in Females [Phase 1]

View source ↗

Summary

This is a Phase 1 dose-response study of VA106483 conducted in females with nocturia. The trial has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Nocturia

Drugs mentioned

• VA106483

Snippet

Sponsor: Vantia Ltd | Conditions: Nocturia | Phase 1 | Status: COMPLETED